Back to Results

Bavarian Nordic A/S ADR (BVNRY)

Bavarian Nordic A/S ADR is a depositary receipt listed on OTC Markets that represents common stock in Bavarian Nordic A/S, a biotechnology company focused on vaccines. Through the underlying issuer, the business develops, manufactures, and supplies vaccines for smallpox and monkeypox under the IMVAMUNE, IMVANEX, and JYNNEOS brands, along with human rabies, tick-borne encephalitis, cholera, and typhoid vaccines sold under names including Rabipur/RabAvert, Encepur, Vaxchora, and Vivotif/Typhoral. The company is also advancing MVA-BN WEV, which is in phase 2 development for encephalitis viruses. Bavarian Nordic A/S operates across North America, Europe, Asia, the Middle East, and other international markets. The company was incorporated in 1992 and is headquartered in Hellerup, Denmark.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-BVNR.Y
$12.52
35.2% Upside
Undervalued
—
—
—
Great
—
—
—
0.0%
November 13, 2026
11.9x
1.1x
2.3x
2.135 B
1.829 B
1.0%
99.8%
21.9
—
180.9%
Send a message
Valuation • Fair Value

Bavarian Nordic A/S ADR (OTC-BVNR.Y) Fair Value by Valuation Model

Compare the primary fair value estimate for Bavarian Nordic A/S ADR (OTC-BVNR.Y) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$12.52

Estimated upside of 35.2% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$13.69

Discounted cash flow valuation reference.

Ben Graham Formula Value

$8.61

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

$11.46

Earnings power value estimate.

Comps Fair Value

$11.53

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Bavarian Nordic A/S ADR (OTC-BVNR.Y) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Bavarian Nordic A/S ADR (OTC-BVNR.Y)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

921.4 M

Current operating scale indicator.

Revenue Forecast

857.6 M

Forward revenue estimate.

EBITDA

216.5 M

Current operating profitability reference.

EBITDA Forecast

241.7 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Bavarian Nordic A/S ADR (OTC-BVNR.Y) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Bavarian Nordic A/S ADR (OTC-BVNR.Y)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Great

Positive financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-2.98

No elevated caution signal from this screen.

Altman Z-Score

21.9

Relatively strong balance-sheet zone.

FCF / Net Income

180.9%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Bavarian Nordic A/S ADR (OTC-BVNR.Y). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Bavarian Nordic A/S ADR (OTC-BVNR.Y)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

November 13, 2026

Days to Earnings

115

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Bavarian Nordic A/S ADR (OTC-BVNR.Y), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Bavarian Nordic A/S ADR (OTC-BVNR.Y) Stock Forecast & Technical Outlook

Review Bavarian Nordic A/S ADR (OTC-BVNR.Y) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Bavarian Nordic A/S ADR (OTC-BVNR.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Bavarian Nordic A/S ADR (OTC-BVNR.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Bavarian Nordic A/S ADR (OTC-BVNR.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Bavarian Nordic A/S ADR (OTC-BVNR.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Bavarian Nordic A/S ADR (OTC-BVNR.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Bavarian Nordic A/S ADR (OTC-BVNR.Y)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for Bavarian Nordic A/S ADR (OTC-BVNR.Y) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

Bavarian Nordic A/S ADR (OTC-BVNR.Y) Stock FAQ

Quick answers about Bavarian Nordic A/S ADR (OTC-BVNR.Y) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$12.52
Estimated upside 35.2%
Valuation Rating
Undervalued
Estimated upside of 35.2%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Great
Current financial-health read

The current fair value estimate for Bavarian Nordic A/S ADR (OTC-BVNR.Y) is $12.52. This implies an estimated upside of 35.2% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 35.2% versus the current market price.

An analyst price target for Bavarian Nordic A/S ADR (OTC-BVNR.Y) is not currently available in the latest data file.

The current financial health read for Bavarian Nordic A/S ADR (OTC-BVNR.Y) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Bavarian Nordic A/S ADR (OTC-BVNR.Y) is November 13, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Bavarian Nordic A/S ADR (OTC-BVNR.Y) is 11.9x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Bavarian Nordic A/S ADR is 2.135 B.

The current enterprise value listed for Bavarian Nordic A/S ADR is 1.829 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Bavarian Nordic A/S ADR is OTC-BVNR.Y, and the stock is listed on OTC Markets.

Bavarian Nordic A/S ADR (OTC-BVNR.Y) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Bavarian Nordic A/S ADR is 1.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Bavarian Nordic A/S ADR is 99.8%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on OTC Markets View more

CSL Ltd (CSLLY) CSL Ltd (CSLLY)
Swedish Orphan Biovitrum AB ADR (BIOV.F) Swedish Orphan Biovitrum AB ADR (BIOV.F)
Grifols SA ADR (GIKLY) Grifols SA ADR (GIKLY)
Mesoblast Ltd (MEOBF) Mesoblast Ltd (MEOBF)
Galapagos NV (GLPGF) Galapagos NV (GLPGF)
Pharma Mar SAU (PHMMF) Pharma Mar SAU (PHMMF)
Biogaia AB ADR (BIOGY) Biogaia AB ADR (BIOGY)
Kuros Biosciences AG (CSBTF) Kuros Biosciences AG (CSBTF)
Clinuvel Pharmaceuticals Ltd (CLVLF) Clinuvel Pharmaceuticals Ltd (CLVLF)
Northwest Biotherapeutics Inc (NWBO) Northwest Biotherapeutics Inc (NWBO)
Spectral Med Inc (EDTXF) Spectral Med Inc (EDTXF)
Cytodyn Inc (CYDY) Cytodyn Inc (CYDY)
Innate Pharma (IPHYF) Innate Pharma (IPHYF)
Vaxart Inc (VXRT) Vaxart Inc (VXRT)
CapForce Inc (CFOR) CapForce Inc (CFOR)
Adocia SA ADR (ADOCY) Adocia SA ADR (ADOCY)
Nuo Therapeutics Inc (AURX) Nuo Therapeutics Inc (AURX)
Cell Source Inc (CLCS) Cell Source Inc (CLCS)
Protext Mobility Inc (TXTM) Protext Mobility Inc (TXTM)
MindMaze Therapeutics Holding SA (RLFTF) MindMaze Therapeutics Holding SA (RLFTF)
Sernova Corp (SEOVF) Sernova Corp (SEOVF)
Microbix Biosystems Inc. (MBXBF) Microbix Biosystems Inc. (MBXBF)
Resverlogix Corp. (RVXCF) Resverlogix Corp. (RVXCF)
Medicenna Therapeutics Corp (MDNAF) Medicenna Therapeutics Corp (MDNAF)